CSPG4 and neoplasm: Intravenous injection of 5–10 mg/kg α-CSPG4 rIgE into Wistar Albino Glaxo (WAG) rats, with dosage selected based on previous studies of safety and anti-tumor efficacy of MOv18 IgE in a similar rat model,15 induced temporary mild to moderate adverse effects, such as labored respiration, prostration, piloerection and reduced responsiveness, which resolved within 30 minutes of injection.